April Chen

April Chen is a highly experienced Principal Scientist currently at Innoviva Specialty Therapeutics, Inc. since January 2023, with a notable history at Entasis Therapeutics, Inc. from 2015 to 2023, where design and execution of mechanistic ADME work were pivotal for NDA filing of the Phase III drug product Durlobactam. April Chen's expertise includes significant contributions in DMPK across various projects, such as ETX0462 and ETX0282CPDP, with strong collaboration within cross-disciplinary teams. Previous roles include Scientist positions at AstraZeneca, Amgen, Novartis Institute of Biomedical Research, and Millennium Pharmaceuticals, with consistent involvement in PK studies, method development, and high-throughput analysis. April Chen holds a Bachelor's degree in Analytical Chemistry from the University of Science and Technology of China and a Master of Science in Analytical Chemistry from Rutgers, the State University of New Jersey.